Details on previous lines of therapy
| Therapy details . | n = 50 . |
|---|---|
| Time from diagnosis to randomization, y | |
| Median (95% CI) | 3 (2-4) |
| ≤3 y, n (%) | 23 (50) |
| 3-6 years, n (%) | 18 (39) |
| Number of lines, median (range) | 3 (1-10) |
| 2, n (%) | 16 (32) |
| 3, n (%) | 19 (38) |
| ≥3, n (%) | 11 (22) |
| Prior lines of therapy, exposed/refractory, (%) | |
| Lenalidomide | 100/86 |
| Bortezomib | 96/56 |
| Alkylator | 100/90 |
| Anthracyclines | 26/50 |
| Last prior therapy | 76* |
| Autologous transplantation | 76† |
| Allogeneic transplantation | 2† |
| Therapy details . | n = 50 . |
|---|---|
| Time from diagnosis to randomization, y | |
| Median (95% CI) | 3 (2-4) |
| ≤3 y, n (%) | 23 (50) |
| 3-6 years, n (%) | 18 (39) |
| Number of lines, median (range) | 3 (1-10) |
| 2, n (%) | 16 (32) |
| 3, n (%) | 19 (38) |
| ≥3, n (%) | 11 (22) |
| Prior lines of therapy, exposed/refractory, (%) | |
| Lenalidomide | 100/86 |
| Bortezomib | 96/56 |
| Alkylator | 100/90 |
| Anthracyclines | 26/50 |
| Last prior therapy | 76* |
| Autologous transplantation | 76† |
| Allogeneic transplantation | 2† |